Member Info for stephen11

Thanks bobminer,

I'm just doing some due diligence. Thinking this share could be quite volatile, so maybe going to buy monthly. A type of pound/cost averaging, but a fantastic long-term prospect.

What's the craic with EMH?

I see this share as a fantastic long term prospect.

If I am correct, the Sonora mine has the potential to produce 35,000 tonnes of lithium per year, when open!

Genuine question! What is the current UK price of lithium, per tonne?

And came back as doozy?

https://www.lse.co.uk/rns/ABDX/trading-update-jbwvd5gxcoaylpw.html

Hi Grim,

Abington lost their DHSC contract on the 21st Feb 2021. Additionally, they are still owed 6.7m from DHSC and they announced this in the RNS above. Hence, the drop in price. Around -30% I think.

https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2?utm_medium=email&utm_source=govdelivery

In the mean time, more authorisations as above!

1/ Genedrive 96-SARS-COV-2kit
- Huge worldwide potential
- 97.6% sensitivity and 98.2% specificity, compared to poor lateral flow test performance (sometimes as high as 50% false positives)
- Agreement with BC started 28th Jan 2021. Sales will materialise, though lead times and sales cycles should be considered
- Regulatory approval for Thailand
- FDA frustrating, though the pace of approvals is accelerating

2/ Pathogen Detection (Bioplex): supplier to US military
- Development contract worth owner 10 million
- 500 kits over 3 years
- Partnership with MountainHorse: this will help develop a broader customer base

3/ Antibiotic induced hearing loss test
- World first
- Worldwide neo-natal hearing loss market worth 35-50 million annually (very niche market)
- Launch summer 2021 to UK and Ireland. Worldwide potential thereafter
- 100% accuracy in testing

4/ World first decentralised qualitative molecular HCV test
- Routes to market impacted by COVID
- Good medium to long-term potential
- High efficacy in a recent peer reviewed study

5/ Listed on the PHE chosen contractors list
- Potential for a share of the 3 billion budgeted future spend

In Development

1/ Genedrive Saliva Test
- 15/20 minute rapid turnover
- Target market: schools/offices/travel etc.
- High accuracy unlike lateral flow tests

2/ Point of care test for tuberculosis
- On hold due to COVID, though good future potential for 2022/2023.

Other important points
- Healthy cash to burn ratio
- High stock levels to fulfil orders
- European ministry of health opportunity. Potential for a low double digit millions of pound order to be delivered in a short period of time

These are the facts but do your own research and make up your own minds.

Good luck all

1/ Genedrive 96-SARS-COV-2kit
- Huge worldwide potential
- 97.6% sensitivity and 98.2% specificity, compared to poor lateral flow test performance (sometimes as high as 50% false positives)
- Agreement with BC started 28th Jan 2021. Sales will materialise, though lead times and sales cycles should be considered
- Regulatory approval for Thailand
- FDA frustrating, though rates of approvals are improving

2/ Pathogen Detection (Bioplex): supplier to US military
- Development contract worth owner 10 million
- 500 kits over 3 years
- Partnership with MountainHorse: this will help develop a broader customer base

3/ Antibiotic induced hearing loss test
- World first
- Worldwide neo-natal hearing loss market worth 35-50 million annually (very niche market)
- Launch summer 2021 to UK and Ireland. Worldwide potential thereafter
- 100% accuracy in testing

4/ World first decentralised qualitative molecular HCV test
- Routes to market impacted by COVID
- Good medium to long-term potential
- High efficacy in recent peer reviewed study

In Development

1/ Genedrive Saliva Test
- 15/20 minute rapid turnover
- Target market: schools/offices/travel etc.
- High accuracy unlike lateral flow tests

2/ Point of care test for tuberculosis
- On hold due to COVID, though good future potential for 2022/2023.

Other important points
- Healthy cash to burn ratio
- High stock levels to fulfil orders
- European ministry of health opportunity. Potential for a low double digit millions of pound order to be delivered in a short period of time

These are the facts but do your own research and make up your own minds.

Good luck all.

Good share starresnstoff,

Another source confirming how erroneous the results are from LFTs. Almost 1 in 3 inaccurate.

The UK is crying out for an accurate PCR test!

https://uk.yahoo.com/news/uk-health-regulator-concerned-over-134226105.html

I see the UK health regulator is catching on to how innacurate lateral flow tests are.

Some very conservative estimates flying about today.

I'll be holding medium to long-term for a 10 bagger.

This is not just a COVID stock. Exponential growth to come from other products (e.g., hearing loss etc.), in addition to world beating pandemic diagnostics.

All to play for!

https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2?utm_medium=email&utm_source=govdelivery

More dropping by the day!....got to be GDRs turn soon.

Wholeheartedly agree BigBench - great work going on at GDR headquarters...this share is a steal at this price (at least Dick Turpin wore a mask)!

Published in a peer reviewed journal with a high impact factor. What's not to like!

This proves what any long term holder already knows that GDR are not just a COVID stock. Couple this with the hearing loss test, equals medium term growth.

And a very positive RNS at that!

I'm calling 80p at close and hoping that is a conservative estimate!

GLA.

https://news.sky.com/story/covid-19-indian-double-mutation-variant-arrives-in-britain-and-has-hallmarks-of-very-dangerous-virus-12276922

Sadly, it is reported that the Indian variant has reached the UK. You would think the need for fast, accurate testing is now, more than ever.

Come on Mr Hanclock - give us a share of that 3 billion. Don't want to be greedy - 5% will do. LOL.

GLA.

Got it, thanks. Yes - good to monitor the rate of new approvals, indeed.

Thanks for sharing Imphobe,

Just to confirm?....is it the CDRH industry link that an individual should tick to get FDA and EUA updates for Genedrive...there are numerous links!

This looks like a great resource.

In the Stock Watch section of the Daily Mail, as below:

"GENEDRIVE rose after it made it on to a Public Health England list of approved suppliers for two types of specialist tests.
Hospitals and other health bodies can strike deals with the diagnostics company to provide COVID tests and screen for potential hearing loss in new born babies. But Manchester-based Genedrive has not sealed any new deals since being put on the list. Shares in the group, which has surged in value since the start of the pandemic, rose 7.5pc, or 5p, to 72p."

GLA.

Well said BigBench,

And don't forget about the potential low digit millions contract with a European country!

All to play for!

GLA